Guangzhou Angke Immunobiological Technology

Guangzhou Angke Immunobiological Technology is a clinical-stage biotechnology company based in China, specializing in the development of next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on addressing unmet medical needs in both hematological malignancies and solid tumors, utilizing its proprietary cell therapy platforms. Its pipeline includes candidates targeting CD19 and BCMA for blood cancers, as well as GPC3 and Claudin 18.2 for solid tumors like liver and gastric cancers. Angke Bio aims to improve the efficacy and safety of immunotherapy through innovative genetic engineering and cell manufacturing processes.